Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-4700 MERS vaccine study in healthy volunteers
PACTR202012691703415Phase 2Not yet recruiting
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- May 2021
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of INO-4700 in Middle East respiratory syndrome (MERS), sponsored by Inovio Pharmaceuticals, Inc. Planned start May 2021; status: not yet recruiting.
02
Drugs
INO-4700
03
Conditions
Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on PACTR202012691703415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202012691703415.